agilon health, inc. (AGL) experienced a significant pre-market plunge of 5.23% on Wednesday, following the company's mixed fourth-quarter 2024 earnings results and disappointing guidance for the upcoming fiscal year 2025.
While the healthcare services company reported strong revenue growth of 44% year-over-year in Q4 2024, reaching $1.52 billion, its earnings metrics fell short of expectations. agilon health reported an adjusted loss per share of $0.26, wider than analysts' estimates, and an adjusted EBITDA loss of $83.97 million, significantly lagging projections.
However, the primary concern for investors appears to be the company's weak outlook for fiscal 2025. agilon health provided revenue growth guidance of just -2.2% year-over-year at the midpoint, a sharp deceleration from the impressive 40.7% growth achieved in 2024. Additionally, the projected 2025 adjusted EBITDA guidance of -$75 million fell short of expectations, highlighting continued profitability challenges amid what management termed a "challenging Medicare Advantage environment."
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。